© 1997 American Heart Association, Inc.
Articles |
Induction of Vascular SMC Proliferation by Urokinase Indicates a Novel Mechanism of Action in Vasoproliferative Disorders
From the Max-Planck-Institute, Kerckhoff-Klinik, Bad Nauheim, Germany (S.M.K., C. Kost, K.T.P.); the Thrombosis Research Institute, London, UK (O.B., C. Kanthou); and the Center for Molecular and Vascular Biology, Katholieke Universiteit Leuven, Leuven, Belgium (H.R.J.).
Abstract The urokinase-type plasminogen activator (UPA) and its receptor are expressed in the vasculature and are involved in cell migration and remodeling of the extracellular matrix in the neointima. Vessels with atherosclerosis or neointimal hyperplasia, when compared with normal vessels, contain high UPA activity as well as increased levels of UPA receptor. In this study, we have identified the stimulation of vascular smooth muscle cell proliferation as a novel activity for UPA in the vessel wall. High-molecular-weight-UPA (12-200 nmol/L range) stimulated DNA synthesis and cell proliferation, which was half that induced by fetal calf serum or by platelet-derived growth factor-BB. UPA did not induce growth of endothelial cells, and tissue-type plasminogen activator showed no activity on either cell type. Induction of proliferation required the complete UPA molecule but was independent of the proteolytic activity of UPA, whereas neither the amino-terminal fragment nor the catalytic domain by itself was mitogenic. UPA also stimulated c-fos/c-myc mRNA expression and mitogen-activated protein kinase activity in smooth muscle cells. Blocking monoclonal antibodies against the UPA receptor and the enzymatic removal of receptors were ineffective in inhibiting the mitogenic effect of UPA, suggesting a UPA receptor–independent mechanism. Thus, we provide evidence for a novel function of UPA on vascular smooth muscle cell proliferation that, together with its previously documented involvement in regulating pericellular proteolysis-related events and cell migration, provides additional evidence for a role in the pathogenesis of atherosclerosis/restenosis.
Key Words: urokinase • proliferation • neointima • smooth muscle
This article has been cited by other articles:
 |
|
 |
|
  B. Fuhrman, J. Khateeb, M. Shiner, O. Nitzan, R. Karry, N. Volkova, and M. Aviram Urokinase Plasminogen Activator Upregulates Paraoxonase 2 Expression in Macrophages Via an NADPH Oxidase-Dependent Mechanism Arterioscler. Thromb. Vasc. Biol., July 1, 2008; 28(7): 1361 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liu, D. J. Cao, I. M. Sainz, Y.-L. Guo, and R. W. Colman The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization Am J Physiol Cell Physiol, July 1, 2008; 295(1): C257 - C267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Kwak, S. Mitra, K. Bdeir, D. Strassheim, J. S. Park, J. Y. Kim, S. Idell, D. Cines, and E. Abraham The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with {alpha}V{beta}3 integrins J. Leukoc. Biol., October 1, 2005; 78(4): 937 - 945. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sokabe, K. Yamamoto, N. Ohura, H. Nakatsuka, K. Qin, S. Obi, A. Kamiya, and J. Ando Differential regulation of urokinase-type plasminogen activator expression by fluid shear stress in human coronary artery endothelial cells Am J Physiol Heart Circ Physiol, November 1, 2004; 287(5): H2027 - H2034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Bernstein, R. S. Greenberg, L. Taliana, and S. K. Masur Urokinase Anchors uPAR to the Actin Cytoskeleton Invest. Ophthalmol. Vis. Sci., September 1, 2004; 45(9): 2967 - 2977. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Schweinitz, T. Steinmetzer, I. J. Banke, M. J. E. Arlt, A. Sturzebecher, O. Schuster, A. Geissler, H. Giersiefen, E. Zeslawska, U. Jacob, et al. Design of Novel and Selective Inhibitors of Urokinase-type Plasminogen Activator with Improved Pharmacokinetic Properties for Use as Antimetastatic Agents J. Biol. Chem., August 6, 2004; 279(32): 33613 - 33622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Lindstedt, M. J. Leskinen, and P. T. Kovanen Proteolysis of the Pericellular Matrix: A Novel Element Determining Cell Survival and Death in the Pathogenesis of Plaque Erosion and Rupture Arterioscler. Thromb. Vasc. Biol., August 1, 2004; 24(8): 1350 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Khanna Concerted effect of transforming growth factor-{beta}, cyclin inhibitor p21, and c-myc on smooth muscle cell proliferation Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H1133 - H1140. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jo, K. S. Thomas, A. V. Somlyo, A. P. Somlyo, and S. L. Gonias Cooperativity between the Ras-ERK and Rho-Rho Kinase Pathways in Urokinase-type Plasminogen Activator-stimulated Cell Migration J. Biol. Chem., March 29, 2002; 277(14): 12479 - 12485. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Ma, D. J. Webb, M. Jo, and S. L. Gonias Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells J. Cell Sci., March 11, 2002; 114(18): 3387 - 3396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Padro, R. M. Mesters, B. Dankbar, H. Hintelmann, R. Bieker, M. Kiehl, W. E. Berdel, and J. Kienast The catalytic domain of endogenous urokinase-type plasminogen activator is required for the mitogenic activity of platelet-derived and basic fibroblast growth factors in human vascular smooth muscle cells J. Cell Sci., January 5, 2002; 115(9): 1961 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Webb, K. S. Thomas, and S. L. Gonias Plasminogen Activator Inhibitor 1 Functions as a Urokinase Response Modifier at the Level of Cell Signaling and Thereby Promotes MCF-7 Cell Growth J. Cell Biol., February 20, 2001; 152(4): 741 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. A. Ploplis, I. Cornelissen, M. J. Sandoval-Cooper, L. Weeks, F. A. Noria, and F. J. Castellino Remodeling of the Vessel Wall after Copper-Induced Injury Is Highly Attenuated in Mice with a Total Deficiency of Plasminogen Activator Inhibitor-1 Am. J. Pathol., January 1, 2001; 158(1): 107 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Mishima, A. P. Mazar, A. Gown, M. Skelly, X.-D. Ji, X.-D. Wang, T. R. Jones, W. K. Cavenee, and H.-J. S. Huang A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin PNAS, July 5, 2000; (2000) 150239497. [Abstract] [Full Text]
|
|
|
|
 |
|
 A J Wilson and P R Gibson Role of urokinase and its receptor in basal and stimulated colonic epithelial cell migration in vitro Gut, July 1, 2000; 47(1): 105 - 111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. HAJ-YEHIA, T. NASSAR, B. S. SACHAIS, A. KUO, K. BDEIR, A. B. AL-MEHDI, A. MAZAR, D. B. CINES, and A. A.-R. HIGAZI Urokinase-derived peptides regulate vascular smooth muscle contraction in vitro and in vivo FASEB J, July 1, 2000; 14(10): 1411 - 1422. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. H. Xing and S. A. Rabbani Regulation of Urokinase Production by Androgens in Human Prostate Cancer Cells: Effect on Tumor Growth and Metastases in Vivo Endocrinology, September 1, 1999; 140(9): 4056 - 4064. [Abstract] [Full Text]
|
|
|
|
|
|
D. H.D. Nguyen, A. D. Catling, D. J. Webb, M. Sankovic, L. A. Walker, A. V. Somlyo, M. J. Weber, and S. L. Gonias Myosin Light Chain Kinase Functions Downstream of Ras/ERK to Promote Migration of Urokinase-type Plasminogen Activator-stimulated Cells in an Integrin-selective Manner J. Cell Biol., July 12, 1999; 146(1): 149 - 164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Koopman, J. Slomp, A. C. W. de Bart, P. H. A. Quax, and J. H. Verheijen Mitogenic Effects of Urokinase on Melanoma Cells Are Independent of High Affinity Binding to the Urokinase Receptor J. Biol. Chem., December 11, 1998; 273(50): 33267 - 33272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. D. Nguyen, D. J. Webb, A. D. Catling, Q. Song, A. Dhakephalkar, M. J. Weber, K. S. Ravichandran, and S. L. Gonias Urokinase-type Plasminogen Activator Stimulates the Ras/Extracellular Signal-regulated Kinase (ERK) Signaling Pathway and MCF-7 Cell Migration by a Mechanism That Requires Focal Adhesion Kinase, Src, and Shc. RAPID DISSOCIATION OF GRB2/SOS-SHC COMPLEX IS ASSOCIATED WITH THE TRANSIENT PHOSPHORYLATION OF ERK IN UROKINASE-TREATED CELLS J. Biol. Chem., June 16, 2000; 275(25): 19382 - 19388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mishima, A. P. Mazar, A. Gown, M. Skelly, X.-D. Ji, X.-D. Wang, T. R. Jones, W. K. Cavenee, and H.-J. S. Huang A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin PNAS, July 18, 2000; 97(15): 8484 - 8489. [Abstract] [Full Text] [PDF]
|
|